ArticleStem cell research & therapy2026
HC-HA/PTX3 from amniotic membrane reprograms human corneal fibroblasts to neural crest progenitors by switching from canonical to noncanonical TGFβ signaling.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHC-HA/PTX3 (a complex formed by high molecular weight hyaluronan covalently linked to heavy chain 1 of inter-α-trypsin inhibitor and tightly bound to pentraxin 3) is a unique extracellular matrix from human amniotic membrane that exerts an anti-scarring action and reprograms human corneal fibroblasts (HCF) and myofibroblasts to corneal stromal keratocytes in the absence of transforming growth factor β1 (TGFβ1) by downregulating canonical Smad-mediated signaling and upregulating bone morphogenetic protein (BMP) signaling. It remains unclear whether HC-HA/PTX3 can further reprogram HCF into neural crest (NC) progenitors in the presence of TGFβ1.
methodsHuman corneal fibroblasts were seeded on plastic, immobilized hyaluronic acid (HA) or HC-HA/PTX3 or on plastic with or without soluble HA and HC-HA/PTX3 in DMEM + 10% fetal bovine serum (FBS), with or without various inhibitors with or without TGFβ1. Transcript expression of NC and signaling markers was determined by RT-qPCR. Immunostaining was performed to monitor cytolocalization of signaling markers and α-smooth muscle actin (α-SMA). Raft separation before Western blot was used to study protein distributions in both rafts. Western blot and ELISA were used to measure relative protein level.
resultsHerein, we show for the first time that in the presence of exogenous TGFβ1, HC-HA/PTX3 continues to reprogram HCF into NC progenitors by upregulating mRNA expression of NC markers, confirmed by successful induction into human corneal endothelial cells, highlighted by hexagonal shape, mRNA expression of corneal endothelial markers and junctional staining of corneal endothelial markers such as Na-K-ATPase, α-catenin, β-catenin, F-actin, N-cadherin, p120 and ZO-1 but the lack of fibrogenic marker S100A4. Such reprogramming requires suppression of TGFβ1 SMAD-mediated canonical signaling that starts from HC-HA/PTX3 binding with CD44 to sequester type II TGFβ receptor (TβRII) in lipid raft and ends with downregulation of TβRII by nuclear translocation of cyclin D1. Mechanistically, nuclear translocation of cyclin D1 is mediated by activation of transforming growth factor-beta-activated kinase 1-transcription factor Jun (TAK1-cJUN) noncanonical signaling because of type I TGFβ receptor (TβRI) and type III TGFβ receptor (TβRIII) (without TβRII) in non-lipid raft as well as by nuclear translocation of CD44 intracellular domain (CD44ICD) formed by Membrane Type 1 Matrix Metalloproteinase (MT1MMP)/γ-secretase cleavage to facilitate such reprogramming.
conclusionsThus, HC-HA/PTX3 from amniotic membrane can be deployed as a new strategy to reverse scar toward regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.